60 results about "Genetic transfer" patented technology

The invention provides a grouper microinjection method, and belongs to the technical field of aquaculture. According to the method, grouper eggs are injected by utilizing a grouper microinjection needle, the microinjection needle is prepared by calcining a glass capillary tube by utilizing a needle pulling instrument, and the parameters of the needle pulling instrument are set as P = 500mW, HET = 720ms, PULL = 60, VEL = 20mu m / s and TIME = 250ms; the outer diameter of the glass capillary tube is 1.0 mm, the inner diameter of the glass capillary tube is 0.75 mm, and the length of the glass capillary tube is 10 cm. The method for injecting the grouper eggs with the micro-injection needle is simple and easy to operate, exogenous gene transfer and endogenous gene accurate editing of the grouper can be realized by adopting the method disclosed by the invention, the target gene editing efficiency is high, and powerful support is provided for deeply researching gene functions of the grouper and cultivating excellent culture varieties.

This product is a work cell for cell therapy manufacturing, automating the entire manufacturing process, including cell concentration, separation, activation, gene transfer using viral vectors or electroporation, expansion culture, filling, finishing, and formulation. This product can provide a self-contained cleanroom environment with a robotic work cell, all within the size of a conference room or a small pickup truck.

The present invention provides polynucleotide vectors for high expression of heterologous genes. Some vectors further comprise novel elements that further improve expression. The gene transfer systems can be used in methods, for example, gene expression, bioprocessing, gene therapy, insertional mutagenesis, or gene discovery.

The present invention relates to a method for cultivating transgenic plants having increased anthocyanin content and enhanced tolerance to biotic and abiotic stress environments. The method comprises transferring a bHLH35 gene into recipient plants using a genetic engineering transformation method, to obtain transgenic plants having increased anthocyanin content and tolerance to biotic and abiotic stress environments. The bHLH35 gene may be selected from a ChbHLH35 gene from Corydalis hemidicentra or an AtbHLH35 gene from Arabidopsis thaliana.

The application discloses a Buster transposon system and application thereof, and the system comprises AnBT, CrBT, HvBT, LcBT and LlBT transposons and corresponding transposases, the nucleotide sequences of the AnBT, CrBT, HvBT, LcBT and LlBT transposons are shown in SEQ ID No. 1-5, and the transposases are wild type or enhanced type. The application obtains key elements such as target site repeat (TSD) and terminal inverted repeat (TIR) of the AnBT, CrBT, HvBT, LcBT and LlBT transposons and corresponding transposase sequences through molecular reconstitution, and constructs a set of gene transfer vector systems. The AnBT, CrBT, HvBT, LcBT and LlBT vector systems can effectively mediate gene transfer through cell verification, and have great application potential in transgenic animal preparation and gene therapy.

Tumor-specific T cell receptor (TCR) gene transfer enables specific and potent immune targeting of tumor antigens. The canonical cancer-testis antigen, NY-ESO-1, is not expressed in normal tissues but is aberrantly expressed across a broad array of cancer types. It has also been targeted with A2-restricted TCR gene therapy without adverse events or notable side effects. To enable the targeting of NY-ESO-1 in a broader array of HLA haplotypes, we isolated TCRs specific for NY-ESO-1 epitopes presented by four MHC molecules: HLA-A2, -B07, -B18, and -C03. Using these TCRs, we have developed an approach to extend TCR gene therapies targeting NY-ESO-1 to patient populations beyond those expressing HLA-A2.

The present invention provides a method for treating an auditory neuropathy spectrum disorder in a subject comprising transferring the gene of DFNB59 via an adeno-associated virus (AAV) vector to the subject.

The present invention refers to hyperactive variants of a transposase of the transposon system Sleeping Beauty (SB). The invention further refers to corresponding nucleic acids producing these variants, to a gene transfer system for stably introducing nucleic acid(s) into the DNA of a cell by using these hyperactive variants of a transposase of the transposon system Sleeping Beauty (SB) and to transposons used in the inventive gene transfer system, comprising a nucleic acid sequence with flanking repeats (IRs and / or RSDs). Furthermore, applications of these transposase variants, the transpsoson, or the gene transfer system are also disclosed such as gene therapy, insertional mutagenesis, gene discovery (including genome mapping), mobilization of genes, library screening, or functional analysis of genomes in vivo and in vitro. Finally, pharmaceutical compositions and kits are also encompassed.

The present invention provides a method and apparatus for identifying horizontally transferred sequences from bacterial genomes in recipient insect genomes, relating to the field of biotechnology. The method provided by the present invention for identifying horizontally transferred sequences from bacterial genomes in recipient insect genomes more comprehensively and accurately identifies and analyzes fragments horizontally transferred from a certain type of bacteria to the genome of this species at the whole genome level; based on the horizontally transferred sequence fragments, horizontally transferred genes, gene fragments, and non-coding region fragments are further identified. This provides a comprehensive analysis of horizontal gene transfer between the genomes of a certain eukaryote and a certain type of bacteria, laying a solid, comprehensive, and reliable foundation for further research into the effects of horizontally transferred genes (fragments) on eukaryotes.

To provide a method for producing a γδT cell population which expresses functional TCR or CAR by preparing large quantities of γδT cells with high purity and efficiently introducing a foreign gene encoding TCR or CAR into the obtained γδT cells.SOLUTION: The present invention provides a method for efficiently producing highly pure γδT cells introduced with foreign genes by culturing in the presence of IL-7 and IL-15 after stimulating the γδT cells with a bisphosphonic acid ester derivative, followed by gene introduction. When a T cell receptor (TCR) or a chimeric antigen receptor (CAR) is introduced as the foreign gene, the γδT cells in which TCR and CAR are functionally expressed can be obtained.SELECTED DRAWING: None

This invention discloses a method for establishing a horizontal gene transfer system between wolfberry and tomato and obtaining transformed roots. Using tomato and wolfberry (both belonging to the Solanaceae family) as starting materials, the method reduces the lignin content of wolfberry cells, eliminates the isolation layer between distantly grafted cells, and connects the grafted cells of the two species. Adventitious roots are induced at the grafting site of the tomato scion by treating it with different auxins. Morphological and molecular biological studies demonstrate that horizontal gene transfer occurred between wolfberry and tomato cells mediated by grafting, and the induced adventitious roots are transformed roots from wolfberry to tomato. This invention establishes a technical system for efficient transfer of wolfberry genes to tomato and obtains transformed roots, achieving complementary advantages between herbaceous and woody plant genetic resources. Tomato plants with transformed root systems exhibit good root vigor, strong plant growth, and a long growth cycle. Obtaining transformed roots is of great significance for improving tomato yield, quality, and resistance.

An engineered transposable element, a gene transfer system comprising same, a method for using same and a kit. A disclosed composition, and the disclosed system and method can be used to insert heterologous nucleic acids into target nucleic acids in vitro or in cells.

The application discloses a method for normalizing and comparing horizontal gene transfer (HGT) network, comprising the following steps: S1, using Bayesian probability model to normalize HGT according to sequencing amount; S2, in the HGT network, each genome is represented as a vertex, and if HGT occurs between two genomes, there is an edge between the two vertices; S3, using different classification levels to annotate genome sequence, and obtaining HGT network of different classification levels; S4, analyzing HGT network through several topological properties of graph density, transitivity, homophily and algebraic connectivity. The graph density, transitivity, homophily and algebraic connectivity are used to describe the network, and the HGT network is compared among samples in different groups, so that a new analysis direction is provided for the correlation between metagenome and human phenotype, and the metagenome can be more systematically modeled and analyzed by calculating various topological properties to analyze the HGT network.

To provide nucleic acid sequences, expression vectors (e.g., vector genomes) and plasmids, compositions and viral vectors in which the nucleic acid encodes Factor IX (e.g. human Factor IX).SOLUTION: A nucleic acid sequence encodes human Factor IX protein, where the nucleic acid has a reduced number of CpG di-nucleotides compared to a wild-type sequence encoding human Factor IX.SELECTED DRAWING: None

The present invention provides polynucleotide vectors for high expression of heterologous genes. Some vectors further comprise novel transposons and transposases that further improve expression. Further disclosed are vectors that can be used in a gene transfer system for stably introducing nucleic acids into the DNA of a cell. The gene transfer systems can be used in methods, for example, gene expression, bioprocessing, gene therapy, insertional mutagenesis, or gene discovery.

This disclosure relates to adeno-associated virus variants capable of performing astrocyte-specific gene transfer. Administration of a recombinant viral vector containing nucleic acid encoding an AAV capsid protein mutant according to this disclosure enables the transfer and expression of therapeutic genes into specific astrocytes, thus demonstrating significant efficacy in the prevention or treatment of brain diseases.

The invention relates to a hybrid peptide consisting of amino acid sequences that bind nucleic acids on one side and cell membrane on the other side, in the fields of biology, genetics and chemistry. The invention particularly relates to a hybrid peptide developed to ensure the transfer of genes into the cell in the treatment of genetic diseases and incurable diseases such as some types of cancer.

Provided are cells that are resistant to mobile genetic elements or horizontal gene transfer, and methods for obtaining said cells. Also provided are methods for preventing the horizontal transfer of genetic information between a mobile genetic element and a first cell, cells making use of new genetic codons schemes and related subject matter, kits comprising mutually orthogonal cells, and mobile genetic elements. Also provided are methods of altering the susceptibility of a gene to mutations that alter the encoded amino acid sequence, methods for evolving or improving a protein, and methods for rendering a target gene more resistant to mutation. Additionally provided are uses of the cells for making polymers and methods comprising using the cells for making polymers.

The present application relates to the technical field of genetic engineering, and particularly relates to a salicylic acid glycosyltransferase and use thereof. The present application finds a new gene (nucleotide sequence as shown in SEQ ID NO. 3) in highland barley, the protein (amino acid sequence as shown in SEQ ID NO. 4) expressed by the gene can convert salicylic acid into salicylic acid glucoside, and improve the level of highland barley resistance to powdery mildew. The present application also performs in-vitro expression on the gene fragment, obtains the salicylic acid glycosyltransferase, and successfully prepares salicylic acid glucoside by taking glucose as a glycosyl donor and salicylic acid as a receptor in an in-vitro reaction. The present application also transfers the gene into tobacco, so that the salicylic acid glycosyltransferase is also expressed in the tobacco plant, further produces salicylic acid glucoside, and improves the value. The new gene, the recombinant vector, the recombinant bacteria, the protein and the transgenic plant provided by the present application all have good application prospects.

This invention discloses a method for remediating halogenated hydrocarbon pollution based on functional plasmid transformation, belonging to the field of environmental microbial remediation technology. The method first extracts plasmid DNA carrying functional genes from organobacteria with reductive dechlorination capabilities (organobacteria with halogen respiration). Then, the functional plasmid DNA and electron donors are directly added to halogenated hydrocarbon-contaminated samples containing indigenous microorganisms to construct a bio-enhanced remediation system. Finally, the system is cultured under anaerobic conditions to transform the functional plasmid into the indigenous microorganisms, thereby endowing or enhancing the indigenous microorganisms with the ability to reductively dechlorinate halogenated hydrocarbon pollutants. This invention avoids the ecological risks of directly introducing exogenous live bacteria. Through plasmid-mediated horizontal gene transfer, it rapidly activates and enhances the function of in-situ microbial communities, significantly improving the degradation rate and thoroughness of halogenated hydrocarbon pollutants, and providing an efficient, safe, and universally applicable technical means for in-situ bioremediation of contaminated sites.

The present invention addresses the problem of providing a chimeric envelope protein that pseudotypes a virus, and also providing efficient gene transfer and gene expression techniques to lymphocytes such as B cells, CD4 positive T cells, and CD8 positive T cells contained in peripheral blood and immortalized cells derived from these cells, said techniques being characterized by using an RNA virus vector having the aforesaid chimeric protein. In a gene transfer method using a single-stranded RNA virus vector such as a Sendai virus vector or a stealth RNA vector, the virus is pseudotyped by using, as the envelope proteins of viral particles, a chimeric F protein having a morbillivirus-derived F protein region and a chimeric H protein having a morbillivirus-derived H protein region.

To provide a technique for more surely achieving a higher viable cell rate while adopting a transposon method for CAR gene transfer in preparation of CAR-T cells.SOLUTION: Disclosed is a method for preparing a genetically modified T cell that expresses a chimeric antigen receptor, which comprises the following steps (i) to (iv): (i) a step of culturing the genetically modified T cell in a monocyte-depleted T cell-containing cell population; A step of preparing non-proliferative cells holding a viral peptide antigen, which are obtained by performing a culture treatment in the presence of a viral peptide antigen and a treatment for losing proliferation ability; (ii) a step of obtaining genetically modified T cells in which a target antigen-specific chimeric antigen receptor gene is introduced by a transposon method from a T cell-containing cell population subjected to a monocyte-reducing treatment; (iii) a step of mixing and co-culturing the non-proliferative cells prepared in step (i) and the genetically modified T cells obtained in step (ii); and (iv) a step of collecting cells after culture.SELECTED DRAWING: None

The present invention provides muscle-derived progenitor cells that show long-term survival following transplantation into body tissues and which can augment soft tissue following introduction (e.g. via injection, transplantation, or implantation) into a site of soft tissue. Also provided are methods of isolating muscle-derived progenitor cells, and methods of genetically modifying the cells for gene transfer therapy. The invention further provides methods of using compositions comprising muscle-derived progenitor cells for the augmentation and bulking of mammalian, including human, soft tissues in the treatment of various functional conditions, including malformation, injury, weakness, disease, or dysfunction. In particular, the present invention provides treatments and amelioration for urinary incontinence and other urinary tract pathologies.

According to the eukaryote level gene transfer identification method and device, the storage medium and the computer equipment provided by the invention, after the target protein sequence of the high-quality genome of the target eukaryote is extracted, the target protein sequence can be compared with the protein sequence in the NR database; screening the protein sequences in the comparison result according to a preset screening condition to obtain a plurality of candidate sequences corresponding to the target protein sequence and a donor sequence corresponding to each candidate sequence, and then performing multi-sequence comparison on each candidate sequence and the corresponding donor sequence, and constructing a corresponding gene topological structure according to a multi-sequence comparison result of each candidate sequence, and determining a biological group in which each gene topological structure is located, so that the candidate sequence, in which the gene topological structure is located in the prokaryotic biological group, in each candidate sequence can be used as a gene sequence from prokaryotic horizontal transfer. And according to a gene topological structure, automatically eliminating non-conforming candidate sequences.

This application provides novel viral envelope glycoproteins for pseudotyping viral vectors, novel designs of synthetic antigen receptors (SARs), novel signaling chains for constructing SARs, novel antigen-binding domains, and novel methods for producing SAR-expressing cells. These novel methods and compositions are widely used in cell therapy.

Provided in the present invention are a hepatitis B virus receptor OATP and the use thereof. Specifically, provided in the present invention is the use of a substance in the preparation of an agent for preventing and / or treating hepatitis B virus (HBV) and / or hepatitis D virus (HDV) infections in an animal or diseases related to said infections, wherein the substance prevents or reduces the interaction between HBV and / or HDV and an organic anion transporting polypeptide (OATP) in the animal, and / or prevents or reduces the expression and / or function of OATP in the animal. Further provided in the present invention are a cell model and an animal model having susceptibility to HBV and / or HDV that are obtained by means of transferring an exogenous SLCO gene into a cell or expressing an exogenous OATP protein, and a method for establishing the models; a method for delivering a drug by means of targeting OATP, and a drug delivery vehicle targeting OATP; and an OATP-targeted delivery polypeptide vehicle derived from a hepadnaviridae surface antigen.

The invention relates to adeno-associated virus (AAV) serotype AAV-Rh74 and related AAV vectors, and AAV-Rh74 and related AAV vector mediated gene transfer methods and uses. In particular, AAV-Rh74 and related AAV vectors target polynucleotides to cells, tissues or organs for expression (transcription) of genes encoding therapeutic proteins and peptides, and polynucleotides that function as or are transcribed into inhibitory nucleic acid sequences.

Methods are provided for enhancing the genetic modification of target cells by automated centrifugal inoculation within a functionally closed cell processing platform. The process begins with the introduction of a cell suspension into a conical cell processing cartridge (CPC) that facilitates the settling and concentration of target cells. Genetic modification is achieved by injection of a gene transfer vector into the CPC, followed by controlled centrifugal inoculation, thereby enhancing vector-cell interactions by centrifugal force while maintaining optimal temperature and conditions. Optical sensors and automated feedback systems monitor and adjust centrifugation parameters to maximize transduction efficiency and cell viability. The methods include precise mixing, reagent delivery, washing to remove contaminants, and harvesting of genetically modified cells, all performed in a sterile environment. Additional features include buoyant microbubble separation, multi-modal centrifugation, and automated fluid handling via transfer syringe cartridges, ensuring efficient, contamination-free cell processing suitable for therapeutic applications.

The purpose of the present invention is to maintain and proliferate T cells, which are in a composition containing the T cells, into a cell group suitable for gene transfer. The present invention pertains to a method for culturing T cells characterized by comprising a step for bringing a composition containing T cells into contact with a composition containing a T cell surface antigen identification substance. The method is also characterized in that, in the composition containing T cells, the amount of the T cell surface antigen identification substance added is 0.0001-2.0 μg and / or 0.0001-20 pmol in terms of antigen recognizing moiety, per 106 T cells.